Medical Press Release - Page 3 of 12 - Medika Life : Keeping you informed

ACOG issues a statement to its members on the temporary withdrawal of the Johnson & Johnson vaccine following reports of rare blood clotting condition.

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

Medika Life - August 6, 2020

European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

Medika Life - August 6, 2020

The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

AI-Driven Model Supports Safer and More Precise Blood Sugar Management After Heart Surgery

Corundum Convergence Institute Launches to Catalyze Funding for Research and Innovation in Neuroscience and Systems Biology

StuffThatWorks and The Marfan Foundation to Engage in Pilot Program

Intellihealth Chief Medical Officer, Dr. Leon Igel, Honored as American Diabetes Association Greater New York Research Dinner Medical Honoree of the Year

LATEST

TRENDING

Medika’s Call for Food Aid for Starving Filipino Children

Lover, the App That Helps Women Reach Orgasm

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

The 50 Most Influential Leaders in Pharmacy 2022 Awards

The Nation’s Only Virtual At-Home Detox Programs from Workit Health Expands

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

FINN Partners Brings Aboard the Pharmacy Podcast Network

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

South University Announces New MSPA Program at West Palm Beach Campus

Parnell Pharmaceuticals Announces Nomovid™ Antiviral Nasal Spray

EDITORS CHOICE

HealthTap Launches Care Orchestration to Drive Timely Use of Employee Benefits

ACOG Statement on the Johnson & Johnson COVID-19 Vaccine

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories